首页> 外文期刊>Life sciences >In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein.
【24h】

In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein.

机译:人P-糖蛋白的体外浓度依赖于苯妥英和苯巴比妥的转运,而不是依托昔布胺的转运。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: One possible mechanism for epilepsy drug resistance is overexpression of P-glycoprotein in the blood-brain barrier, but whether (or which) antiepileptic drugs (AEDs) are transported by P-gp remains unclear. We evaluated AEDs as P-gp substrates using cell monolayers. MAIN METHODS: Bi-directional transport assays and concentration equilibrium transport assays (CETAs) were performed for phenytoin (PHT), phenobarbital (PB), and ethosuximide (ESM) using wildtype Madin-Darby Canine Kidney II cell line MDCKII and porcine renal endothelial cell line LLC-PK1 cells and these cells transfected with human MDR1 cDNA to express P-gp. KEY FINDINGS: Wildtype cells demonstrated no efflux transport of PHT, PB, or ESM. In CETAs, both MDR1-transfected cell lines transported PHT from basolateral to apical when PHT loading concentrations were 5 or 10, but not 20microg/ml. MDCK-MDR1 cells transported PB when initial concentrations were 10 or 20, but not 5microg/ml. LLC-MDR1 did not transport PB. P-gp inhibitor verapamil blocked efflux transport. MDR1-transfected cells did not transport ESM at 5.6 or 56microg/ml. Bi-directional transport assays demonstrated weak transport for PHT but not PB or ESM. SIGNIFICANCE: Human P-gp transports PHT and PB, but not ESM, in a concentration dependent manner. CETA may be more sensitive than bi-directional assays to detect transport of drugs with high passive diffusion. Potential P-gp substrates should be tested at clinically relevant concentration ranges.
机译:目的:癫痫药耐药性的一种可能机制是血脑屏障中P-糖蛋白的过度表达,但尚不清楚P-gp是否转运抗癫痫药(AED)。我们使用细胞单层将AED评估为P-gp底物。主要方法:使用野生型Madin-Darby犬肾脏II细胞系MDCKII和猪肾内皮细胞对苯妥英钠(PHT),苯巴比妥(PB)和ethosuximide(ESM)进行了双向转运测定和浓度平衡转运测定(CETA)系LLC-PK1细胞,并用人MDR1 cDNA转染这些细胞以表达P-gp。主要发现:野生型细胞未显示PHT,PB或ESM的外排转运。在CETA中,当PHT上样浓度为5或10,但不是20microg / ml时,两种MDR1转染的细胞系都将PHT从基底外侧转运到顶端。当初始浓度为10或20,而不是5microg / ml时,MDCK-MDR1细胞转运PB。 LLC-MDR1没有传输PB。 P-gp抑制剂维拉帕米可阻断外排转运。 MDR1转染的细胞未转运5.6或56microg / ml的ESM。双向转运分析证明PHT转运较弱,但PB或ESM转运较弱。意义:人P-gp以浓度依赖性方式转运PHT和PB,但不转运ESM。 CETA可能比双向测定法更灵敏,以检测具有高被动扩散性的药物转运。潜在的P-gp底物应在临床相关浓度范围内进行测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号